My lab aims to determine how tumor hypoxia, and the hypoxia-inducible factors, HIF-1 and HIF-2, drive outcomes that promote cancer progression and resistance to therapy.

Dr. Mei Yee Koh Dr. Koh is Founder/Director and Chief Executive Officer of Kuda Therapeutics. She has an established record of accomplishment in hypoxia and HIF signaling, and has contributed to the development of a number of novel cancer therapies such as PX478 (HIF-1α inhibitor) and PX-12 (thioredoxin inhibitor), all currently in clinical ...

Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia. Mol Cancer Res, 17 (5), 1220-1232. (Read full article)

Aug 9, 2024 · Assistant Professor of Pharmacology and Toxicology. Solid Tumor Hypoxia, Kidney Cancer, Liver Cancer, HIF-1 and HIF-2, Ferroptosis. All solid tumors and their metastases suffer from regions of oxygen deprivation, also known as hypoxia.

Mei Yee Koh. University of Utah. Verified email at utah.edu. Oncology Hypoxia Experimental therapeutics. Articles Cited by Public access. Title. Sort. Sort by citations Sort by year Sort by title. ... MY Koh, M Gagea, T Sargis, R Lemos Jr, G Grandjean, A Charbono, ... Hepatology 63 (5), 1576-1591, 2016. 46:

Kuda Therapeutics, led by co-founder and CEO, Dr. Mei Yee Koh, and co-founder and CFO, Mr. Travis Ehlinger, identified a molecule that specifically blocks HIF production and induces tumor cell death through ferroptosis.

Oct 16, 2024 · Mei Yee Koh, PhD CEO , Kuda Therapeutics, Inc Dr. Koh has spent her 20-year career investigating the cellular signaling pathways that impact tumor progression and response to therapy.

Mei KOH, Research Assistant Professor | Cited by 2,217 | of Sanford Burnham Prebys Medical Discovery Institute, California | Read 26 publications | Contact Mei KOH

Jul 1, 2024 · View the The University of Utah profile of MEI YEE KOH. Including their grants and teaching activities.